The Swiss biotech space hotted up last week as two of its leading funds, run by HBM Partners, picked up more than $200 million in a couple of trade sale exits, while Evolva S.A. announced...

Gemin X raised C$19.1 million (US$12.6 million) in its second round of financing through Sanderling Venture Partners; Canadian Medical Discoveries Fund; Sofinov; BioCapital Investments; MVI Medical Venture Investments; and Business Development Bank of Canada. Gemin...

Qbiogene (Montreal, Quebec) raised $20 million in a venture financing. Investors included Vertex Technology Fund; Quebec Solidarity Fund; BioCapital Investments; Double Helix ; New Medical Technologies; PolyTechnos Venture-Partners; Schweizerische Gesellschaft fur Aktienhandel & Research; and...

Toolkit companies that went public this year enjoy a robust premium on their valuations compared to more mature toolkit plays as well as profitable product companies. Indeed, comparing market cap to projected 2001 revenues, a...

Arpida (Basel, Switzerland) raised $23 million in a venture financing. Investors included BioCapital Investments; HealthCap; New Medical Technologies; and 3i Group. The company is developing second generation antimicrobial compounds to treat infections caused by drug-resistant...

In hot equity markets, U.S. companies traditionally have not been bashful about floating an IPO and then returning in short order with a follow-on. But European biotech companies still face the challenge of convincing investors...

The amount of money being thrown at toolkit IPOs in 2000 still reflects the genomics craze that began in the fourth quarter last year. So far this year, toolkit companies are beating up product IPOs...

NewcoGen Group and OneLiberty Ventures today were to announce the formation of Applied Genomic Technology Capital, a venture capital vehicle solely focused on genomics companies. The fund - with the genetically appropriate acronym of "AGTC" - has...

BioCapital Investments (TSE:BCK.UN), a publicly traded health care limited partnership, postponed its proposed C$46.5 million (US$31.5 million) Canadian offering due to market conditions. BioCapital was to invest the proceeds in both public and private health...